Puma and CANBridge cancel licensing deal for $20m

Los Angeles company Puma Biotechnology and Beijing-based CANBridge Pharmaceuticals have cancelled a 2018 licensing deal which gave the latter exclusive rights to a breast cancer drug in China.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

AstraZeneca sues Dr Reddy's over breast cancer drug

14 February 2017 AstraZeneca has filed a patent infringement claim against Dr Reddy's Laboratories over the drug Faslodex (fulvestrant) intramuscular injection, a treatment for breast cancer.

Americas

Genentech adds to breast cancer pipeline with Seragon buyout

2 July 2014 Genentech has entered into an agreement to buy Seragon, a San Diego-based biotech company that specialises in developing treatments that target hormone-driven cancers, for up to $1.7 billion.

More on this story

Americas

AstraZeneca sues Dr Reddy's over breast cancer drug

14 February 2017 AstraZeneca has filed a patent infringement claim against Dr Reddy's Laboratories over the drug Faslodex (fulvestrant) intramuscular injection, a treatment for breast cancer.

Americas

Genentech adds to breast cancer pipeline with Seragon buyout

More on this story

Americas

AstraZeneca sues Dr Reddy's over breast cancer drug

14 February 2017 AstraZeneca has filed a patent infringement claim against Dr Reddy's Laboratories over the drug Faslodex (fulvestrant) intramuscular injection, a treatment for breast cancer.

Americas

Genentech adds to breast cancer pipeline with Seragon buyout